
|Articles|November 15, 2022
Utilizing Automated High-Throughput SEC Native Mass Spectrometry for mAb Screening
Author(s)Agilent Technologies
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.